Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements

Rhea-AI Summary

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has announced that it has regained compliance with NASDAQ Marketplace Rule 5250(c)(1). This follows the filing of its Quarterly Reports on Form 10-Q for the periods ended March 31, June 30, and September 30, 2021. As a result, the matter with NASDAQ is now closed. Adamis focuses on developing specialty products for allergy, opioid overdose, and respiratory diseases, with its approved SYMJEPI and ZIMHI injection products for emergency treatments.

Positive

• Regained compliance with NASDAQ Marketplace Rule 5250(c)(1), closing the matter with NASDAQ.

Negative

• None.

SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“NASDAQ”) notifying the company that based on the company’s filing of its Quarterly Reports on Form 10-Q for the periods ended March 31, 2021, June 30, 2021 and September 30, 2021, the company has regained compliance with NASDAQ Marketplace Rule 5250(c)(1), which requires timely filing of periodic reports with the Securities and Exchange Commission, and that the matter is now closed.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company’s SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company’s ZIMHI (naloxone) Injection is approved for the treatment of opioid overdose. Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is underway. For additional information about Adamis Pharmaceuticals, please visit www.adamispharmaceuticals.com and follow us on us on Twitter and LinkedIn.

Contact:

Investor Relations at
Adamis Pharmaceuticals Corporation
(858) 997-2400 option 3
IR@adamispharma.com

FAQ

What compliance issue did Adamis Pharmaceuticals resolve?

Adamis Pharmaceuticals resolved a compliance issue with NASDAQ concerning the timely filing of its Quarterly Reports.

When did Adamis Pharmaceuticals regain NASDAQ compliance?

Adamis Pharmaceuticals regained NASDAQ compliance on November 23, 2021.

What is the stock symbol for Adamis Pharmaceuticals?

The stock symbol for Adamis Pharmaceuticals is ADMP.

What therapeutic areas does Adamis Pharmaceuticals focus on?

Adamis Pharmaceuticals focuses on allergy, opioid overdose, and respiratory diseases.

What products does Adamis Pharmaceuticals have FDA approval for?

Adamis Pharmaceuticals has FDA approval for SYMJEPI (epinephrine) and ZIMHI (naloxone) injections.